The National Institutes of Health (NIH) is offering a funding opportunity titled "Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R01 Clinical Trial Not Allowed)" aimed at supporting research into the immunometabolic changes induced by HIV that may elevate the risk of tuberculosis (TB) and hepatitis B virus (HBV) in individuals on combination antiretroviral therapy (cART). This initiative seeks to fund investigator-led studies that explore the long-term effects of HIV-related alterations in immune metabolism on disease progression and treatment responses, with a focus on identifying biomarkers and innovative therapies to mitigate these risks. The grant is open to a wide range of eligible applicants, including higher education institutions, non-profits, and for-profit organizations, with no cost-sharing requirements. Interested parties should note that the application submission deadlines range from April 2025 to January 2028, and they can direct inquiries to NIH Grants Information at grantsinfo@nih.gov. For further details, applicants can refer to the full announcement available at https://grants.nih.gov/grants/guide/pa-files/PAR-25-315.html.